Sirolimus Adverse Event Profile in a Non-Clinical Trial Cohort of Heart Transplantation Patients.

Ann Transplant · 2021 · PMC7824988 · PMID 33462174

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

Compared to the MMF group, patients in the sirolimus group were more likely to have CAV, more likely to have received daclizumab induction versus OKT3, and with a notable trend of having more underlying renal insufficiency.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.